Fig. 5.
The effect of age at start of treatment with or without a prior fracture (T-score at or below −2.5 SD) on the cost-effectiveness of denosumab vs. comparators. Asterisk (*), Denosumab is cost saving
* Denosumab is cost-saving
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.